#1 Clinical Trials Search in Europe

Cinnarizine

Cinnarizine, a versatile medication primarily known for treating vertigo and motion sickness, is being investigated in various clinical trials for its potential benefits in other medical conditions. This article explores the use of Cinnarizine in different clinical settings, including its possible effects on primary aldosteronism and simulator sickness prevention. We’ll delve into the ongoing research and potential applications of this drug beyond its traditional uses.

Table of Contents

What is Cinnarizine?

Cinnarizine is a medication that belongs to a class of drugs called calcium channel blockers. It is known by several brand names, including Stugeron, Stunarone, and Cinarin[1]. This medication works by affecting the way calcium moves in and out of cells, which can have various effects on the body.

Uses of Cinnarizine

Cinnarizine is used to treat several conditions:

  • Vertigo and Nausea: It is commonly prescribed for vertigo (a sensation of spinning or dizziness) and nausea[1].
  • Motion Sickness: Cinnarizine is used to prevent and treat motion sickness, including a condition called Simulator Sickness that can affect pilots during flight simulator training[2].
  • Primary Aldosteronism: This is a condition where the adrenal glands produce too much of a hormone called aldosterone. Cinnarizine is being studied as a potential treatment for this condition[1].

Dosage and Administration

The dosage of cinnarizine can vary depending on the condition being treated:

  • For Primary Aldosteronism: In a current study, patients are given 30 mg of cinnarizine three times a day[1].
  • For Motion Sickness: A dose of 50 mg is being studied for prevention of simulator sickness[2].
  • For Methamphetamine-Induced Psychosis: In one study, patients were given one tablet of cinnarizine (referred to as “stugeron”) three times a day after meals[3].

It’s important to note that these dosages are from specific studies and may not represent the typical dosage for all patients. Always follow your doctor’s instructions when taking any medication.

Potential Side Effects

While the specific side effects of cinnarizine are not detailed in the provided information, it’s important to be aware that all medications can have side effects. Common side effects of calcium channel blockers like cinnarizine may include dizziness, headache, or fatigue. Always discuss potential side effects with your healthcare provider.

Ongoing Research

Cinnarizine is currently being studied for new potential uses:

  • Primary Aldosteronism: Researchers are investigating whether cinnarizine can help lower aldosterone levels in people with primary aldosteronism. This condition causes high blood pressure due to excess aldosterone production. The study is comparing cinnarizine to another calcium channel blocker called nifedipine to see if cinnarizine’s effect on a specific type of calcium channel (called Cav1.3) makes it more effective for this condition[1].
  • Simulator Sickness: A study is comparing cinnarizine to another medication called scopolamine for preventing simulator sickness in helicopter pilots. This research aims to find the most effective treatment with the fewest side effects that could impact a pilot’s performance during training[2].

These studies highlight the potential for cinnarizine to be used in treating conditions beyond its current approved uses. However, it’s important to remember that more research is needed before these new uses can be confirmed and approved.

Study Focus Cinnarizine Dosage Comparison Drug Primary Outcome
Primary Aldosteronism 30 mg oral, three times daily Nifedipine (60 mg daily) Change in aldosterone levels
Simulator Sickness Prevention 50 mg oral, single dose Scopolamine (0.6 mg) Reduction in motion sickness symptoms
Methamphetamine-Induced Psychosis 1 tablet, three times daily N/A (part of standard regimen) N/A (not primary focus of study)

FAQ

  • What is Cinnarizine primarily used for? Cinnarizine is primarily used to treat vertigo, motion sickness, and nausea. It's known by brand names such as Stugeron, Stunarone, and Cinarin.
  • How is Cinnarizine being studied in relation to primary aldosteronism? Researchers are investigating Cinnarizine as a potential Cav1.3 inhibitor in primary aldosteronism. They're comparing its effects on aldosterone levels and blood pressure to those of nifedipine, a conventional calcium channel blocker.
  • What is the dosage of Cinnarizine used in the primary aldosteronism study? In the primary aldosteronism study, Cinnarizine is administered orally at a dose of 30 mg three times a day for two weeks.
  • How is Cinnarizine being compared to other medications in clinical trials? In one study, Cinnarizine (50 mg) is being compared to scopolamine (0.6 mg) and a placebo for the prevention of simulator sickness in helicopter pilots.
  • Are there any other uses of Cinnarizine mentioned in the clinical trials? In a study on methamphetamine-induced psychosis, Cinnarizine (referred to as Stugeron) is mentioned as part of the institute's medication regimen, given as 1 tablet three times a day after meals.

Ongoing Clinical Trials on Cinnarizine

  • Study of stopping heart failure medications in patients with non-ischemic cardiomyopathy who responded very well to cardiac resynchronization therapy

    Recruiting

    1 1 1 1
    Investigated drugs:
    Spain

  • Study of spironolactone and eplerenone in patients with heart failure with preserved ejection fraction (HFpEF)

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Sweden

Glossary

  • Primary Aldosteronism (PA): A condition where the adrenal glands produce too much of the hormone aldosterone, which can lead to high blood pressure and low potassium levels.
  • Cav1.3: A type of calcium channel in the body that may play a role in aldosterone production. Cinnarizine is being studied as a potential inhibitor of this channel.
  • Mineralocorticoid Receptor Antagonists (MRA): A class of drugs used to treat primary aldosteronism by blocking the effects of aldosterone.
  • CACNA1D mutation: A genetic mutation that affects the Cav1.3 calcium channel and may be associated with some cases of primary aldosteronism.
  • Simulator Sickness: A condition similar to motion sickness that can occur when using flight simulators or other virtual reality environments.
  • Methamphetamine-Induced Psychosis: A mental health condition characterized by hallucinations and delusions that can occur as a result of methamphetamine use.

References

  1. https://clinicaltrials.gov/study/NCT05686993
  2. https://clinicaltrials.gov/study/NCT01198106
  3. https://clinicaltrials.gov/study/NCT01939093